Archives
DRD4, Akt/β-Catenin, and Liver Cancer Resistance
2026-10-08
A 2024 British Journal of Cancer study links elevated DRD4 with liver cancer stem cell-like traits, chemotherapy resistance, and poorer survival, identifying an Akt/β-catenin signaling mechanism. The findings support DRD4 and its downstream pathway as research targets, while remaining bounded by the study’s disease models and the need for independent validation.
Mitochondrial Repair Strategy for Diabetic Periodontitis
2026-10-08
The reference study presents a hierarchically targeted, ROS-responsive nanoparticle–hydrogel platform designed to repair dysfunctional mitochondria in M1 macrophages during diabetic periodontitis. Its in vitro and rat-model findings support a mechanistic link between mitochondrial protection, reduced inflammasome activity, lower inflammation, and improved periodontal bone outcomes, while remaining preclinical.
Amikacin Sulfate: Evidence Beyond the MIC
2026-10-07
Amikacin Sulfate research is best interpreted through a spatial pharmacology lens: activity depends not only on potency, but also on intracellular access and granuloma localization. This article examines the evidence, innovation, and translational limits of targeted amikacin delivery in NTM models.
Cy5 Amine (Non-Sulfonated): Product Overview
2026-10-07
Cy5 amine (SKU A8143) is an APExBIO-listed, non-sulfonated cyanine dye with a primary amino group for conceptual fluorescent labeling research. No matched paper evidence was supplied, so its specifications and application claims are not independently verified here.
ARCA Cy5 EGFP mRNA: Evidence and Research Context
2026-10-06
A source-grounded overview of ARCA Cy5 EGFP mRNA (5-moUTP), its conceptual value for delivery and translation studies, and the limits of extrapolating supplier descriptions or therapeutic LNP findings to a fluorescent reporter.
Cy5 NHS ester(Et): Product Overview
2026-10-06
Cy5 NHS ester(Et), SKU A8769, is an APExBIO-listed fluorescent dye reagent described for conceptual labeling of primary amines in biomolecules. No matched paper evidence was provided, so this overview is limited to supplier-documented identity and stated scope.
Regorafenib in Melanoma: Evidence and Limits
2026-10-05
A source-grounded overview of Regorafenib (BAY 73-4506), examining its multikinase principles, reported RRM2–ERK/E2F3 findings in melanoma, evidence quality, interpretation, and translational limits.
SAN-Plexus Assembloids and Pacemaker Maturation
2026-10-05
A 2026 Cell Stem Cell study introduces human pluripotent stem cell-derived assembloids that combine sinoatrial node, cardiac plexus, and atrial-like tissues to model neural regulation of pacemaker activity. By integrating electrophysiology, functional assembloid analysis, and spatial transcriptomics, the work identifies a prosaposin–GPR37 signaling program associated with human pacemaker maturation and conduction phenotypes.
TUNEL and Mitochondrial Stress in Glioblastoma
2026-10-04
A source-grounded overview of TUNEL-based DNA fragmentation detection, mitochondrial stress, and apoptosis interpretation in glioblastoma research.
Metal-Chelating L-Phe Nanostructures and ICB
2026-10-03
A 2024 Nature Nanotechnology study reports that metal-ion-chelating L-phenylalanine nanostructures can activate dendritic-cell programs and improve breast and colorectal tumour responses to immune checkpoint blockade in preclinical models. Its central contribution is a mechanistic link between nanostructure-driven ion flux, innate immune signaling, short-term starvation, and tumour-specific cytotoxic T-cell activity.
Sulfo-Cy3 NHS Ester for Reliable Cell Assays
2026-10-02
Learn how Sulfo-Cy3 NHS ester (SKU A8107) can support orthogonal protein-uptake, proliferation, and cytotoxicity workflows when conventional viability readouts are difficult to interpret. This scenario-based guide connects its aqueous compatibility, NHS-ester chemistry, and Cy3 spectral properties with practical assay controls and vascular-biology applications.
Engineering Nonomuraea for Higher A40926 Production
2026-10-01
The reference study combines targeted dbv-cluster engineering with statistically guided medium optimization to improve A40926 production in Nonomuraea gerenzanensis. Deletion of dbv23 and coexpression of dbv3 and dbv20 increased production by 30.6%, while the optimized M9 medium raised the reported yield from 257 to 332 mg l−1, illustrating the value of integrating genetic and process-level interventions.
Cap 1 Luciferase mRNA for Delivery Readouts
2026-10-01
Organ-selective mRNA delivery demands more than a bright reporter: it requires a mechanistically disciplined way to separate cargo performance from carrier biology. This article explains how EZ Cap™ Firefly Luciferase mRNA can support that strategy, using the POST study’s peptide-coded LNP findings as a framework for translational assay design.
ARCA Cy5 EGFP mRNA (5-moUTP) Assay Guide
2026-09-30
Separate nanoparticle uptake from productive protein expression with a dual-readout reporter designed for mammalian-cell delivery studies. This workflow shows how to use Cy5 fluorescence, EGFP translation, microscopy, and flow cytometry to benchmark mRNA carriers while avoiding common interpretation and handling errors.
Masitinib (AB1010): KIT/PDGFR Workflow Guide
2026-09-30
Masitinib (AB1010) is a DMSO-compatible tyrosine kinase inhibitor for focused KIT and PDGFRα/β studies, including selected GIST, mast cell, and mastocytosis research workflows. It should not be used as a broad-spectrum kinase probe or in assays requiring aqueous or ethanol solubility, and product-dossier potency values should not be treated as clinical treatment evidence.
617 records 6/42 page Previous Next First page 上5页 678910 下5页 Last page